Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of "Hold" from Analysts

Key Points

• Pfizer Inc. has received an average recommendation of "Hold" from nineteen analysts, with one sell, twelve hold, four buy, and two strong buy ratings.
• The average one-year target price for Pfizer's stock among analysts is $28.41, with recent target increases from firms like Morgan Stanley and Citigroup.
• Pfizer’s latest earnings report showed $0.78 earnings per share, beating estimates, and a revenue of $14.65 billion, marking a 10.3% increase compared to the same quarter last year.

Shares of Pfizer Inc. (NYSE:PFE - Get Free Report) have received a consensus recommendation of "Hold" from the nineteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, four have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $28.4118.

A number of research analysts have issued reports on the stock. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Wall Street Zen cut shares of Pfizer from a "buy" rating to a "hold" rating in a report on Sunday, September 28th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Pfizer in a report on Saturday, September 27th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a report on Friday.

Pfizer Stock Up 1.1%

Shares of NYSE:PFE opened at $27.37 on Friday. The company has a market cap of $155.59 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 0.88 and a beta of 0.55. The firm's 50-day simple moving average is $24.67 and its 200-day simple moving average is $24.14. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. Pfizer has a fifty-two week low of $20.92 and a fifty-two week high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The business's quarterly revenue was up 10.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts predict that Pfizer will post 2.95 earnings per share for the current year.

Hedge Funds Weigh In On Pfizer

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. GKV Capital Management Co. Inc. acquired a new position in Pfizer during the first quarter worth about $27,000. Curio Wealth LLC raised its position in Pfizer by 36,600.0% during the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after acquiring an additional 1,098 shares during the last quarter. Bayforest Capital Ltd acquired a new position in Pfizer during the first quarter worth about $28,000. North Capital Inc. acquired a new position in Pfizer during the first quarter worth about $28,000. Finally, Harbor Asset Planning Inc. acquired a new position in Pfizer during the second quarter worth about $29,000. Institutional investors and hedge funds own 68.36% of the company's stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.